

Curriculum Vitae Manfred Jung

Personal Data

Title	Prof. Dr.
First name	Manfred
Name	Jung
Current position	Professor of Pharmaceutical Chemistry, University of Freiburg
Current institution(s)/site(s), country	Institute of Pharmaceutical Sciences, Albertstr. 25, 79104 Freiburg, University of Freiburg, Germany
Identifiers/ORCID	0000-0002-6361-7716

Qualifications and Career

Stages	Periods and Details
Degree programme	1990 Federal License as "Apotheker" ("Approbation", Registered Pharmacist) 1989-1990 Internship in a public pharmacy and at the University of Marburg, Germany 1985-1989 Study of Pharmacy at the University of Marburg (Staatsexamen, state exam.), Germany
Doctorate	1990-1993 Dr. rer. nat. with Prof. Dr. W. Hanefeld in Pharmaceutical Chemistry, University of Marburg, Germany
Stages of academic/professional career	2011- Full professor (W3) of Pharmaceutical Chemistry, University of Freiburg, Germany 2003-2010 Professor of Pharmaceutical Chemistry (C3), University of Freiburg, Germany 2001-2002 Senior lecturer (Hochschuldozent) at the Department of Pharmaceutical and Medicinal Chemistry, University of Münster, Germany 1994-2001 Lecturer and researcher (Wissenschaftlicher Assistent) at the Department of Pharmaceutical and Medicinal Chemistry, University of Münster, Germany 2000: Habilitation for Pharmaceutical Chemistry with the thesis "Synthesis and biological activities of new agents for cancer chemoprevention" University of Münster, Germany 1997-1998 Mandatory military service: Pharmacy of the army hospital in Hamm 1993-1994 Postdoctoral studies with Prof. Dr. T. Durst, University of Ottawa, Canada; Synthesis of amino acids by kinetic dynamic resolution (DFG scholar)

Supplementary Career Information

N/A

Activities in the Research System

2024-	Member of the Scientific Board of the German Pharmaceutical Society
2019-2023	Elected member of the Senate of the University of Freiburg, Speaker of the group of Professors in the Senate; participation in recruitment boards for Rector, Vice rectors for Research and for Teaching; Heading recruitment board for the University Council (Universitätsrat)
2015-2018	Dean of the Faculty of Chemistry and Pharmacy, 2018-2019 Vice Dean
2013	Meeting president, Annual meeting German Pharmaceutical Society (DPhG)
2013-2015	Vice Dean of the Faculty of Chemistry and Pharmacy
2012-2024	Vice-Speaker of CRC992 – Medical Epigenetics (MEDEP); Coordinator of the Integrated Research Training Group (IRTG)
2010-2016	German management committee member for the EU COST projects on Epigenetics TD0905 and CM1406

Supervision of Researchers in Early Career Phases

Supervision of 17 doctoral dissertations, 26 Masters/diploma dissertations, 15 Bachelor dissertations (within the last 5 years and ongoing).

Hosting of 4 postdoctoral researchers (within the last 5 years and ongoing).

Scientific Results

Category A

Structure-guided design of a selective inhibitor of the histone methyltransferase KMT9 with cellular activity. Wang S, Klein SO, Urban S, Staudt M, Barthes NPF, Willmann D, Bacher H, Sum M, Bauer H, Peng L, Rennar GA, Gratzke C, Schüle KM, Zhang L, Einsle O, Greschik H, MacLeod C, Thomson CG, **Jung M**, Metzger E, and Schüle R (2024). **Nature Communications** 15, 43. 10.1038/s41467-023-44243-6

Structure-activity studies of 1,2,4-oxadiazoles for the inhibition of the NAD⁺-dependent lysine deacetylase Sirtuin 2. Colcerasa A, Friedrich F, Melesina J, Moser P, Vogelmann A, Tzortzoglou P, Neuwirt E, Sum M, Robaa D, Zhang L, Ramos-Morales E, Romier C, Einsle O, Metzger E, Schüle R, **Groß O**, Sippl W, and **Jung M** (2024). **Journal of Medicinal Chemistry** 67, 10076-10095. 10.1021/acs.jmedchem.4c00229

Generation and in vitro Assessment of HDAC6 Proteolysis Targeting Chimera (PROTACs). Darwish S, Heimbürg T, Ridinger J, Herp D, Schmidt M, Romier C, **Jung M**, Oehme I, and Sippl W (2023). **Methods in Molecular Biology** 2589, 179-193. 10.1007/978-1-0716-2788-4_12

Development of a NanoBRET assay to validate inhibitors of Sirt2-mediated lysine deacetylation and defatty-acylation that block prostate cancer cell migration. Vogelmann A, Schiedel M, Wössner N, Merz A, Herp D, Hammelmann S, Colcerasa A, Komaniecki G, Hong JY, Sum M, Metzger E, Neuwirt E, Zhang L, Einsle O, **Groß O**, Schüle R, Lin H, Sippl W, and **Jung M** (2022). **RSC Chemical Biology** 3, 468-485. 10.1039/D1CB00244A

HaloTag-targeted sirtuin rearranging ligand (SirReal) for the development of proteolysis targeting chimeras (PROTACs) against the lysine deacetylase Sirtuin 2 (Sirt2). Schiedel M, Lehotzky A, Szunyogh S, Oláh J, Hammelmann S, Wössner N, Robaa D, Einsle O, Sippl W, Ovádi J, and **Jung M** (2020), **ChemBioChem** 23, 3371-3376. 10.1002/cbic.202000351

Structure-reactivity relationships on substrates and inhibitors of the lysine deacetylase Sirtuin 2 from *Schistosoma mansoni* (SmSirt2). Monaldi D, Rotili D, Lancelot J, Marek M, Lucidi A, Tomaselli D, Ramos-Morales E, Romier C, Pierce RJ, Mai A, and **Jung M** (2019). **Journal of Medicinal Chemistry** 62, 8733-8759. 10.1021/acs.jmedchem.9b00638

KMT9 mono-methylates histone H4 Lysine 12 and controls proliferation of prostate cancer cells. Metzger E, Wang S, Urban S, Willmann D, Schmidt A, Offermann A, Allen A, Sum M, Obier N, Cottard F, Ulferts S, Preca B-T, Herrmann B, Maurer J, Greschik H, Hornung V, Einsle O, Perner S, Imhof A, **Jung M**, and Schüle R (2019). **Nature Structural and Molecular Biology** 26, 361–371. 10.1038/s41594-019-0219-9

Chemically induced degradation of sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals). Schiedel M, Herp D, Hammelmann S, Swyter S, Lehotzky A, Robaa D, Oláh J, Ovádi J, Sippl W, and **Jung M** (2018). **Journal of Medicinal Chemistry** 61, 482-491. 10.1021/acs.jmedchem.6b01872

Structure-based Development of a Sirtuin 2 Affinity Probe. Schiedel M, Rumpf T, Karaman B, Lehotzky A, Gerhardt S, Ovádi J, Sippl W, Einsle O, and Jung M (2016). **Angewandte Chemie International Edition** 55, 2252-2256. 10.1002/anie.201509843

Selective Sirt2-inhibition by ligand-induced rearrangement of the active site. Rumpf T, Schiedel M, Karaman B, Roessler C, North BJ, Lehotzky A, Olah J, Ladwein KI, Schmidtkunz K, Gajer M, Pannek M, Steegborn C, Sinclair DA, Gerhardt S, Ovadi J, Schutkowski M, Sippl W, Einsle O, and Jung M (2015). **Nature Communications** 6, 6263. 10.1038/ncomms7263

Category B

TIMER Therapeutics GmbH & CoKG, Biotech spinout on epigenetic modulators and PROTACs, Start 04/2023. Other University funders are Schüle R, Metzger E, and Wang S. Secured funding of over 4 million EUR so far.

Specific small molecule inhibitors that block KMT9 methyltransferase activity and function. Schüle R, Wang W, Metzger E, **Jung M**, and Klein S. WO 2023/017152 EP21191163.1 (filed 12.08.2021).

Novel histone methyltransferase inhibitors. Schüle R, Metzger E, Wang S, **Jung M**, Barthes NPF, Breit B, Sarraf D, and Pappert T (2021). Patent: WO2021/053158

Inhibition of histone methyltransferases to treat cancer. Schüle R, Metzger E, Wang S, **Jung M**, Barthes NPF, Pappert T, Breit B, and Sarraf D (2020) Patent: WO2020/058358

Academic Distinctions

2016 Phoenix Pharmacy Science Award for Pharmaceutical Chemistry

2000 Innovation prize (Habilitationenpreis) „Medicinal Chemistry“ of DPhG and GDCh

Other Information

not specified